Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Prochlorperazine repurposed: a new use in clustering tumor surface receptors to support immunotherapy

Written by Louis Gautier, Future Science Group

An ongoing study from a team at the University of Queensland (Brisbane, Australia) has demonstrated the clinical viability of using this inhibitory effect of prochlorperazine to support anticancer immunotherapy. The team recently conducted an uncontrolled, single-center proof-of-concept study to examine the drug’s inhibition of endocytosis in the context of tumor surface receptors and cancer treatment. Prochlorperazine is a well-established, first-generation drug used in the short-term management of psychosis, as well as severe cases of nausea and vomiting. Previous studies have used advanced imaging techniques to quantify the rate of endocytosis in humans. The group found that prochlorperazine was effective in...

To view this content, please register now for access

It's completely free